Allopurinol pharmacogenetics: Assessment of potential clinical usefulness

Pharmacogenomics

Volumn 12, Issue 12, 2011, Pages 1741-1749

  Zineh, Issam ^a   Mummaneni, Padmaja ^a   Lyndly, Jenna ^b   Amur, Shashi ^a   La Grenade, Lois A ^a   Chang, Stephen H ^c   Rogers, Hobart ^a   Pacanowski, Michael A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Office of Surveillance and Epidemiology   (United States)

Author keywords

Adverse reaction; allopurinol; HLA B5801; Johnson syndrome; safety; SCAR; Stevens ; US FDA

Indexed keywords

ALLOPURINOL;

ARTICLE; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL DECISION MAKING; DATA BASE; DRESS SYNDROME; DRUG EXPOSURE; ERYTHEMA MULTIFORME; FOOD AND DRUG ADMINISTRATION; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GOUT; HLA GENE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; KIDNEY DISEASE; PAIN; PHARMACOGENETICS; PRESCRIPTION; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CHILD; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; GENETIC VARIATION; GOUT; GOUT SUPPRESSANTS; HLA ANTIGENS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PHARMACOGENETICS; RISK ASSESSMENT; SKIN DISEASES; STEVENS-JOHNSON SYNDROME;

EID: 82255163561     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.131     Document Type: Article

References (22)

1. Zineh I, Lesko LJ. Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. Per. Med. 6, 359-361 (2009).
2. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 46 (8), 1372-1374 (2007).
3. Zhang W, Doherty M, Bardin T et al. EULAR Standing Committee for International Clinical Studies including Therapeutics. EULAR evidence based recommendations for gout. PartII: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann. Rheum. Dis. 65 (10), 1312-1324 (2006).
4. Sarawate CA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo. Clin. Proc. 81 (7), 925-934 (2006). (Pubitemid 43993484)
5. Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr. Opin. Rheumatol. 21 (2), 143-149 (2009).
6. DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. In: KDD '01: Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. ACM, New York, NY, USA, 67-76 (2001).
7. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25, 381-392 (2002). (Pubitemid 34729136)
8. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica 179 (1), 32-33 (1989). (Pubitemid 19172335)
9. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102 (11), 4134-4139 (2005).
10. Erratum in: Proc. Natl Acad. Sci. USA 102 (17), 6237 (2005).
11. Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19 (9), 704-709 (2009).
12. Lonjou C, Borot N, Sekula P et al. RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18 (2), 99-107 (2008).
13. Kaniwa N, Saito Y, Aihara M et al. JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9 (11), 1617-1622 (2008).
14. Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 215 (1), 86-88 (2007). (Pubitemid 46976024)
15. Kang HR, Jee YK, Kim YS et al. Positive and negative associations of HLA classI alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet. Genomics 21 (5), 303-307 (2011).
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327 (7414), 557-560 (2003). (Pubitemid 37088507)
17. Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergol. Int. 59 (4), 325-332 (2010).
18. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem. J. 429 (3), 435-449 (2010).
19. Puig JG, Casas EA, Ramos TH, Michán AA, Mateos FA. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J. Rheumatol. 16 (6), 842-844 (1989). (Pubitemid 19182978)
20. Khanna D, Fuldeore MJ, Meissner BL et al. The incidence of allopurinol hypersensitivity syndrome: a population perspective. Presented at: The Annual American College of Rheumatology Scientific Meeting (ACR/ARHP). Poster SessionC S672, San Francisco, CA, USA, 23-28 October 2008.
21. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep. 11 (2), 135-140 (2009).
22. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89 (3), 464-467 (2011).